GlassScriptPhysician profile
Leonard J Moss
NPI 1417988262
$3,556.91
in general payments reported to CMS, 2019-2025
31 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,056 · 2020: $416 · 2021: $168 · 2022: $169 · 2023: $147 · 2024: $300 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $445.21 | 2019-2025 | Wegovy |
| Glaxosmithkline, LLC. | $437.73 | 2019-2025 | Penmenvy, Trelegy Ellipta, Arexvy |
| Amgen INC. | $393.47 | 2019-2021 | |
| Pfizer INC. | $312.95 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $294.02 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.07 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $250.50 | 2019-2025 | Zoryve |
| Abbvie INC. | $143.94 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $112.57 | 2019-2024 | Vaxneuvance, Vaxelis |
| Arbor Pharmaceuticals, INC. | $110.79 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $86.04 | 2019 | |
| Lilly USA, LLC | $75.98 | 2019-2020 | |
| Mannkind Corporation | $74.02 | 2019-2020 | |
| Amarin Pharma, INC. | $71.54 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $70.99 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $59.47 | 2019-2020 | |
| Shire North American Group INC | $57.79 | 2019 | |
| Genentech USA, INC. | $42.81 | 2019-2020 | |
| Boston Scientific Corporation | $29.24 | 2019 | |
| Avanir Pharmaceuticals, INC. | $28.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.22 | 2020 | |
| Sanofi-Aventis U.S. LLC | $25.16 | 2019 | |
| Allergan, INC. | $22.05 | 2019 | |
| Corcept Therapeutics | $21.91 | 2024 | Korlym |
| Abbott Laboratories | $20.03 | 2023 | Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.48 | 2024 | Xifaxan |
| Dynavax Technologies Corporation | $18.00 | 2019 | |
| Smith+Nephew, INC. | $15.00 | 2019 | |
| Astellas Pharma US INC | $13.64 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.18 | 2019 | |
| Irhythm Technologies, INC. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.